Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Point-of-Care, Biosensors & Mobile Diagnostics Europe 2021

John T McDevitt's Biography



John T McDevitt, Chair, Department of Biomaterials, New York University College of Dentistry Bioengineering Institute

John T. McDevitt now serves as a Full Professor within the Department of Biomaterials at New York University, is a member of NYU’s Bioengineering Institute and participates as a faculty member in the NYU Department of Chemical and Biomolecular Engineering within the Tandon School of Engineering. Prior to this time, he served for 5 years as the Brown-Weiss Professor of Bioengineering and Chemistry at Rice University and rose through the academic ranks at University of Texas at Austin where he was positioned for 20 years. McDevitt completed his Ph.D. degree in Chemistry from Stanford University.

Professor McDevitt is a pioneer in the development of ‘programmable bio-nano-chip’ technologies. He has a strong track record of translating essential bioscience, artificial intelligence and medical microdevice discoveries into real-world clinical practice. In this capacity, he has served as the Scientific Founder for a number of diagnostic and clinical services companies including OraLiva which features smart diagnostics for early disease detection as well as SensoDx which develops and monetizes programmable diagnostic hardware. McDevitt and his team have raised over $45M in Federal and Foundation support. His recent research has been sponsored by major programs funded by National Institute of Dental and Craniofacial Research (NIDCR) division of the National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) at NIH, Bill and Melinda Gates Foundation, Cancer Prevention Research Institute of Texas (CPRIT), NASA (National Aeronautics and Space Administration), Renaissance Health Service Corporation (Delta Dental of MI), the Army and the United Kingdom’s Home Office Scientific Development Branch.

McDevitt and his team have written more than 200 peer-reviewed scientific manuscripts and have contributed to more than 100 patents and patent applications. This work was recognized with the “2020 People’s Choice Award for the TOPx COVID-19 initiative”, “2016 AACC Wallace H. Coulter Lectureship Award,” “Best of What's New Award” in the Medical Device Category by Popular Science as well as for the “Best Scientific Advances Award” by the Science Coalition. Dr. McDevitt’s individual honors include the Presidential Young Investigator Award, the California Polytechnic Distinguished Alumni Award and the Exxon Education Award. Over the past years, Dr. McDevitt has served as the Principal Investigator for 6 major clinical trials and 2 clinical pilot studies, all involving the programmable bio-nano-chip. Through these clinical efforts, mini-sensor ensembles are being developed for major diseases in the areas of COVID-19 disease severity, oral cancer, cardiac heart disease, trauma, drugs of abuse, ovarian cancer and prostate cancer.

John T McDevitt Image

Development and Deployment of a 'Smart Diagnostic Ecosystem' for Covid-19 and Beyond: Near Real-Time Customization of Programmable Medical Microdevices

Wednesday, 30 June 2021 at 15:00

Add to Calendar ▼2021-06-30 15:00:002021-06-30 16:00:00Europe/LondonDevelopment and Deployment of a 'Smart Diagnostic Ecosystem' for Covid-19 and Beyond: Near Real-Time Customization of Programmable Medical MicrodevicesPoint-of-Care, Biosensors and Mobile Diagnostics Europe 2021 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com

SARS-CoV-2, the virus that causes coronavirus disease (COVID-19), has reached pandemic levels and resulted in significant morbidity and mortality that has affected every inhabited continent. Delays in diagnostic testing and the inability to track infections on a local, international and global basis has hampered the management of the COVID19 pandemic. This pathogenic coronavirus has had a disproportionate impact on the underserved and impoverished. While COVID-19 has yielded devastating consequences, the pandemic has also opened the door for acceleration of core diagnostic capabilities that have the potential to lead to lasting impact for our society. With this vantage point in mid, in the recent past we have launched a series of efforts that target the development and deployment of a ‘smart diagnostics ecosystem’. Here we integrate programmable chip-based diagnostic systems capable of multiplexed measurements alongside clinical decision support tools that utilize strategically chosen nonclinical data elements that elicit signatures that can be used to capture diseases before they spiral out of control, including COVID-19. Using newly established diagnostic models that leverage large COVID-19 databases we have developed, validated and scaled a clinical decision support system and mobile app to assist in COVID-19 severity assessment, management, and care. Model training data from 701 patients with COVID-19 were collected across practices within the Family Health Centers network at New York University Langone Health. A two-tiered model was developed. Tier 1 uses easily available, nonlaboratory data to help determine whether biomarker-based testing and/or hospitalization is necessary. Tier 2 predicts probability of mortality using biomarker measurements (CRP, PCT, D-dimer) and age. Both Tier 1 and Tier 2 models were validated using two external datasets from hospitals in Wuhan, China comprising 160 and 375 patients, respectively. These capabilities have been extended recently to screening of dental patients as well as to the developments of on integrated immunity scoring system. The ecosystem now includes cloud connected databases and AI linked clinical decision support tools that were developed initially for COVID-19, but are now helping to accelerate the arrival of new oncology tools.


Add to Calendar ▼2021-06-28 00:00:002021-06-30 00:00:00Europe/LondonPoint-of-Care, Biosensors and Mobile Diagnostics Europe 2021Point-of-Care, Biosensors and Mobile Diagnostics Europe 2021 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com